Patents Assigned to Athersys, Inc.
-
Publication number: 20040082018Abstract: The present invention relates to methods for using osteocalcin. The invention also relates to methods for using polynucleotides encoding osteocalcin. The invention relates to methods using the osteocalcin polypeptides and polynucleotides as a target for diagnosis and treatment osteocalcin related conditions. The invention further relates to drug-screening methods using the osteocalcin polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the osteocalcin polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the osteocalcin polypeptides and polynucleotides as a target. The invention further related to methods of treating a subject suffering from an osteocalcin mediated condition.Type: ApplicationFiled: October 29, 2002Publication date: April 29, 2004Applicant: Athersys, Inc.Inventors: George Mbella Ekema, Robert W. Mays, Kurt R. Brunden
-
Publication number: 20040081970Abstract: The current disclosure provide a novel human calcium sensing receptor named CaR2 and the nucleotide sequence that encodes the receptor. The disclosure further provides antibodies specific for CaR2. Also disclosed are methods of identifying modulators of the receptor and methods of using the identified modulators to treat calcium receptor mediated conditions.Type: ApplicationFiled: October 29, 2002Publication date: April 29, 2004Applicant: Athersys, Inc.Inventors: George Mbella Ekema, Pieter W. Faber, Benjamin Philip Faga, Gregory B. Foust, John J. Harrington, Paul David Jackson, Robert W. Mays
-
Publication number: 20040018624Abstract: The present invention is directed generally to reduction or inactivation of gene function or gene expression in cells in vitro and in multicellular organisms. The invention encompasses methods for mutating cells using a combination of mutagens, particularly wherein at least one mutagen is an insertional mutagen, to achieve homozygous gene mutation or mutation of multiple genes required cumulatively to achieve a phenotype to create knock-outs, knock-downs, and other modifications in the same cell. The invention is also directed to cells (and libraries thereof) and organisms created by the methods of the invention, including those in which at least one of the genes created by insertional mutagenesis is tagged by means of the insertion sequences thereby allowing identification of the mutated gene(s). The invention is also directed to libraries of mutated cells and their uses.Type: ApplicationFiled: October 22, 2002Publication date: January 29, 2004Applicant: Athersys, Inc.Inventors: John Joseph Harrington, Paul David Jackson, Li Jiang
-
Patent number: 6670185Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins.Type: GrantFiled: January 7, 2000Date of Patent: December 30, 2003Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
-
Publication number: 20030224519Abstract: The present invention is directed generally to reduction or inactivation of gene function or gene expression in cells in vitro and in multicellular organisms. The invention encompasses methods for mutating cells using a combination of mutagens, particularly wherein at least one mutagen is an insertional mutagen, to achieve homozygous gene mutation or mutation of multiple genes required cumulatively to achieve a phenotype to create knock-outs, knock-downs, and other modifications in the same cell. The invention is also directed to cells (and libraries thereof) and organisms created by the methods of the invention, including those in which at least one of the genes created by insertional mutagenesis is tagged by means of the insertion sequences thereby allowing identification of the mutated gene(s). The invention is also directed to libraries of mutated cells and their uses.Type: ApplicationFiled: January 15, 2003Publication date: December 4, 2003Applicant: Athersys, Inc.Inventors: John Joseph Harrington, Paul David Jackson, Li Jiang
-
Publication number: 20030180267Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration.Type: ApplicationFiled: December 30, 2002Publication date: September 25, 2003Applicant: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
-
Patent number: 6623958Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.Type: GrantFiled: January 18, 2000Date of Patent: September 23, 2003Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
-
Patent number: 6602686Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins.Type: GrantFiled: December 7, 1999Date of Patent: August 5, 2003Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
-
Publication number: 20030134421Abstract: The present invention is in the fields of molecular biology, cell biology, and genetics. The invention is directed generally to mutating genes in cells in vitro and in multi-cellular organisms. The invention encompasses methods for mutating genes in cells using polynucleotides that act as insertional mutagens. Such methods are used to achieve mutation of a single gene to achieve a desired phenotype as well as mutation of multiple genes, required cumulatively to achieve a desired phenotype, in a cell or in a multi-cellular organism. The invention is also directed to methods of identifying one or more mutated genes, made by the methods of the invention, in cells and in multi-cellular organisms, by means of a tagging property provided by the insertional mutagen(s). The insertional mutagen thus allows identification of one or more genes that are mutated by insertion of an insertional mutagen.Type: ApplicationFiled: November 4, 2002Publication date: July 17, 2003Applicant: Athersys, Inc.Inventors: John Joseph Harrington, Paul David Jackson, Li Jiang
-
Patent number: 6541221Abstract: Expression of an endogenous gene is activated or increased following integration into a cell, by non-homologous or illegitimate recombination, of (1) an enhancer sequence that activates expression of the gene and (2) a sequence that encodes an amplifiable marker. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides cells containing the enhancer and amplifiable marker sequence and expressing increased amounts of a desired gene. The invention also provides methods for the isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins, including transmembrane proteins, and for the isolation of cells expressing such proteins.Type: GrantFiled: January 11, 2000Date of Patent: April 1, 2003Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
-
Patent number: 6524824Abstract: Expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for the isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins, including transmembrane proteins, and for the isolation of cells expressing such transmembrane proteins which may be heterologous transmembrane proteins. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.Type: GrantFiled: January 12, 2000Date of Patent: February 25, 2003Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
-
Patent number: 6524818Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.Type: GrantFiled: January 18, 2000Date of Patent: February 25, 2003Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
-
Patent number: 6410266Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more ampliflable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.Type: GrantFiled: January 7, 2000Date of Patent: June 25, 2002Assignee: Athersys, Inc.Inventors: John J. Harrington, Stephen Rundlett
-
Patent number: 6361972Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.Type: GrantFiled: January 10, 2000Date of Patent: March 26, 2002Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett